Malaysian botanical drug developer seeks $300 million Nasdaq listing – Reuters
|
Malaysian botanical drug developer seeks 0 million Nasdaq listing
Reuters "We believe that the Nasdaq and American investing community are very life sciences-friendly," FELDA's deputy director-general Muhammad Sufi Mahbub told Reuters. "We should be able to secure better value on the Nasdaq than in any other stock market.". Malaysian botanical drug developer seeks 0 mln Nasdaq listing |
